Single-Center Experience Using Selexipag in a Pediatric Population

Roberto Gallotti, Diana E. Drogalis-Kim,Gary Satou,Juan Alejos

Pediatric cardiology(2017)

引用 28|浏览9
暂无评分
摘要
Pulmonary arterial hypertension (PAH) is a rare and progressive disorder. Current treatment in the pediatric population includes phosphodiesterase 5 inhibitors (PDE-5i), endothelin receptor antagonists (ERA), and both inhaled and intravenous prostacyclin pathway agonists. As of December 22, 2015 the first oral prostacyclin pathway agonist, selexipag (Uptravi ® ), was FDA approved in the US. In this case series, we discuss our single-center experience using selexipag in a pediatric population, composed of both patients with idiopathic PAH, and patients with congenital heart disease and PAH.
更多
查看译文
关键词
Pediatrics,Pulmonary hypertension,Remodulin®,Selexipag,Treprostinil,Uptravi®
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要